...
首页> 外文期刊>Biopharmaceutics and Drug Disposition >Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
【24h】

Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.

机译:oltipraz在小鼠,大鼠,兔和狗中的种间药代动力学缩放和人类药代动力学预测。

获取原文
获取原文并翻译 | 示例

摘要

Dose-independent pharmacokinetics of oltipraz after intravenous and/or oral administration at various doses to mice, rats, rabbits and dogs were evaluated. After both intravenous and/or oral administration of oltipraz to mice (5, 10 and 20 mg/kg for intravenous and 15, 30 and 50 mg/kg for oral administration), rats (5, 10 and 20 mg/kg for intravenous and 25, 50 and 100 mg/kg for oral administration), rabbits (5, 10 and 30 mg/kg for intravenous administration) and dogs (5 and 10 mg/kg for intravenous and 50 and 100 mg/kg for oral administration), the total area under the plasma concentration-time curve from time zero to time infinity (AUC) values of oltipraz were dose-proportional in all animals studied. Animal scale-up of some pharmacokinetics parameters of oltipraz was also performed based on the parameters after intravenous administration at a dose of 10 mg/kg to mice, rats, rabbits and dogs. Linear relationships were obtained between log time-averaged total body clearance (Cl) x maximum life-span potential (MLP) (1 year/h) and log species body weight (W) (kg) (r=0.999; p=0.0015), log Cl (l/h) and log W (kg) (r=0.979; p=0.0209), and log apparent volume of distribution at steady state (V(ss)) (l) and log W (kg) (r=0.999; p=0.0009). The corresponding allometric equations were ClxMLP=49.8 W(0.861), Cl=5.20 W(0.523) and V(ss)=4.46 W(0.764). Interspecies scale-up of plasma concentration-time data for the four species using pharmacokinetic time of dienetichron resulted in similar profiles. In addition, concentrations of oltipraz in a plasma concentration-time profile for humans predicted using the four animal data fitted to the dienetichron time transformation of animal data. Copyright (c) 2005 John Wiley & Sons, Ltd.
机译:评估了对小鼠,大鼠,兔和狗以各种剂量静脉和/或口服给药后奥替拉唑的剂量依赖性药代动力学。给小鼠静脉和/或口服奥替拉唑(静脉内分别为5、10和20 mg / kg,口服为15、30和50 mg / kg)后,大鼠(静脉内和口服分别为5、10和20 mg / kg)口服给药:25、50和100 mg / kg),兔子(静脉给药,分别为5、10和30 mg / kg)和狗(静脉给药,分别为5和10 mg / kg和口服和50和100 mg / kg),在所有研究的动物中,oltipraz从零时到无限时(AUC)值的血浆浓度-时间曲线下的总面积与剂量成比例。还基于以10 mg / kg的剂量静脉内施用给小鼠,大鼠,兔子和狗的参数,对奥替普拉的某些药代动力学参数进行了动物放大。在对数时间平均总体清除率(Cl)x最大寿命潜力(MLP)(1年/小时)和对数物种体重(W)(kg)之间获得线性关系(r = 0.999; p = 0.0015) ,log Cl(l / h)和log W(kg)(r = 0.979; p = 0.0209),以及稳定状态下的对数表观分布体积(V(ss))(l)和log W(kg)(r = 0.999; p = 0.0009)。相应的等速方程为ClxMLP = 49.8 W(0.861),Cl = 5.20 W(0.523)和V(ss)= 4.46 W(0.764)。种间放大使用dienetichron的药代动力学时间的四个物种的血浆浓度-时间数据导致相似的配置文件。另外,使用适合于动物数据的二同步时间转换的四种动物数据预测的人血浆浓度-时间曲线中的奥替普拉斯浓度。版权所有(c)2005 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号